Heath Lukatch is retiring from the Board of Directors, effective July 16, 2026. Concurrently, John Markels was appointed to the Board as a Class II director, effective the same date, with terms to expire at the 2028 annual meeting. Vaxcyte, Inc. is a biotechnology company focused on developing advanced vaccine technology.
